+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 130Years
All Genders
ID05489211

Evaluating Datopotamab Deruxtecan Alone and With Other Anticancer Agents for Advanced or Metastatic Solid Tumors A Phase II Multicenter Study

Led by AstraZeneca · Updated on 2026-09-23

454

Participants Needed

96

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Datopotamab Deruxtecan Dato-DXd alone and combined with other anticancer drugs in patients with advanced or metastatic solid tumors. This Phase II, open-label, multicenter study uses a modular master protocol to assess safety, tolerability, recommended dosing, and effectiveness across several cancer types including endometrial, gastric, prostate, ovarian, colorectal, urothelial, and biliary tract cancers. The study allows simultaneous evaluation of Dato-DXd in various treatment combinations and disease settings. Participants receive Dato-DXd intravenously as monotherapy or combined with approved or novel anticancer agents, varying by cancer subtype. Treatment combinations include capecitabine, 5-Fluorouracil, prednisoneprednisolone, carboplatin, bevacizumab, volrustomig, rilvegostomig, and cisplatin. Each substudy tests either monotherapy or combination therapy tailored to the tumor type. The study follows participants during treatment and a safety follow-up period, with some treatments administered orally or intravenously depending on the agent. Throughout the approximately one-year study period, participants undergo regular assessments including tumor measurement, adverse event monitoring, pharmacokinetic sampling, and specific biomarker evaluations such as PSA, CA-125, and radiographic progression depending on cancer type. Researchers evaluate outcomes like objective response rate, progression-free survival, disease control, and overall survival. Safety is monitored closely during and up to 28 or 90 days after treatment discontinuation. Participants provide tumor samples for tissue analysis and may consent to optional genetic research.

CONDITIONS

Brief Title

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here